Related Experiment Video
Updated: Jan 10, 2026
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
Esophageal Function Testing Identifies Barrett's Esophagus Patients With Pathological Acid Exposure at Risk for
Edoardo Vespa1, Edi Viale1, Ernesto Fasulo1
1Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy; Faculty of Medicine, Università Vita-Salute San Raffaele, Milan, Italy.
Background & Aims:
Pathological esophageal acid exposure may persist in patients with Barrett's esophagus (BE), despite proton pump inhibitor (PPI) administration and symptom control. We aimed to determine the role of esophageal function testing in assessing acid exposure in patients with BE on PPI therapy and predicting disease progression.
Methods:
Multicenter retrospective study of asymptomatic patients with BE with high-resolution manometry and 24-hour pH impedance testing on PPI. Histological findings were recorded at index endoscopy while on the same therapeutic regimen. On pH monitoring, total acid exposure time (AET) >6% was defined as pathological reflux. Receiver operator characteristic analysis was performed to evaluate the predictive performance of AET for neoplasia, using Youden's index to identify the optimal cutoff.
Results:
A total of 135 patients were included (mean age, 58 ± 15 years; 73% male). Median BE length was C1M2, 56 (41%) had long-segment BE. Sixty-eight patients (50%) were on standard-dose PPI. Pathological reflux was identified in 37 patients (27%), of whom 25 (67%) were taking standard-dose PPI. Among the 84 patients (62%) with normal AET (<4%), 34 (40%) were taking standard-dose PPI. On multivariable analysis, standard-dose PPI (adjusted odds ratio [aOR], 3.53; P = .004) and type III esophagogastric junction morphology (aOR, 2.64; P = .036) were independently associated with pathological reflux. Thirteen patients (10%) had neoplasia at index endoscopy (8 low-grade dysplasia, 3 high-grade dysplasia, 2 adenocarcinoma). Pathological reflux was the only independent predictor of neoplasia (aOR, 9.62; P < .001). AET ≥6% predicted neoplasia well (area under the curve, 0.816; 77% sensitivity; 78% specificity).
Conclusions:
Nearly one-third of asymptomatic patients with BE exhibit pathological reflux on pH-monitoring despite PPI treatment. Nonetheless, normal AET is found in another one-third of patients on standard-dose PPI. Pathological reflux is associated with a 9-fold increased risk of neoplasia.
Related Concept Videos
01:21Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:30Esophageal Strictures-I: Introduction
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
01:29Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:
01:26Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...